Business- Page 59

Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort 1 (gluten challenge) of Phase 1b trial in celiac disease (CeD) Completed

WALTHAM, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian

New award includes Xacta 360 subscriptions and cybersecurity services. ASHBURN, Va., Nov. 03, 2026 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for

LONDON and GAITHERSBURG, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that

SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for

WESTFORD, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) reported its financial results for the third quarter ended October 3, 2026. Third Quarter Financial Highlights Bookings increased 22% to

Revenue of $3.6 billion, up 5.7% year over year, with organic revenue growth of 6.4%, the highest in more than three years $375 million of new business wins, up 34% year over year,